Annexon, Inc. Common Stock (ANNX) Stock
Key stats
- Market cap
- $722.30M
- Price / Earnings ratio
- -3.6x
- EPS (TTM)
- -$103.37
- Volume
- Loading
- 52-week high
- $7.18
- 52-week low
- $2.54
Source: third-party data provider, as of October 24, 2026
Compare with ANNX
Recent news

Annexon Q2 Earnings Call Highlights
Annexon Q2 Earnings Call Highlights
ANNX

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNX

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNX

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNX
Technical indicators
- RSI 14
- 44.01
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.18
- MACD histogram
- 0.02
- SMA 50
- $4.37
- Price below SMA 50
- EMA 50
- $4.29
- Price below EMA 50
- SMA 200
- $5.28
- Price below SMA 200
- EMA 200
- $4.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Annexon Q2 Earnings Call Highlights
Annexon Q2 Earnings Call Highlights
ANNX

Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
ANNX

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
ANNX

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
ANNX

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
ANNX

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
ANNX

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
ANNX

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
ANNX
About Annexon, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas E. Love Esq., J.D. | CEO, President & Director | 1968 |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 1958 |
| Ms. Jennifer Lew CPA | Executive VP, CFO & Corporate Secretary | 1973 |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 1961 |
| Ms. Linda A. Fitzpatrick | Chief Human Resources Officer | 1957 |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 1971 |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | — |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | 1958 |
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial | — |
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 44.01
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.18
- MACD histogram
- 0.02
- SMA 50
- $4.37
- Price below SMA 50
- EMA 50
- $4.29
- Price below EMA 50
- SMA 200
- $5.28
- Price below SMA 200
- EMA 200
- $4.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $20.00
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.5 | +6.1 | -29.9 | |||||||||
| 2022 | -37.2 | -41.4 | -42.3 | -4.1 | +16.3 | +26.5 | +28.8 | +30.1 | +7.1 | -23.9 | +15.3 | -6.3 |
| 2023 | +49.1 | -26.0 | -24.7 | +34.4 | -45.1 | +17.3 | +0.0 | -22.3 | -18.9 | +5.6 | +3.8 | +94.0 |
| 2024 | -14.0 | +31.4 | +20.1 | -31.4 | +1.7 | +7.0 | +26.9 | -6.6 | +9.4 | +19.8 | -26.0 | -2.7 |
| 2025 | -30.2 | -25.0 | -19.2 | +2.8 | +9.7 | +13.2 | -2.8 | -15.9 | +47.3 | +4.3 | +42.0 | +21.5 |
| 2026 | +33.0 | -12.2 | +0.4 | +9.5 | -5.7 | +2.3 | -8.1 | -5.9 | -13.5 | -7.5 |



